hailshadow-istockphoto-com

Hailshadow / iStockphoto.com

14 June 2018Americas

PTAB rejects IPR challenges to Gilead patents

The Patent Trial and Appeal Board (PTAB) has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

MSF challenges Gilead patent in China

20 June 2018 Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.

PTAB shoots down tenth I-MAK Gilead challenge

24 July 2018 The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

Biotechnology

PTAB blocks Qiagen’s bid to invalidate diagnostics patent

20 July 2020 Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.

More on this story

MSF challenges Gilead patent in China

20 June 2018 Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.

PTAB shoots down tenth I-MAK Gilead challenge

24 July 2018 The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

Biotechnology

PTAB blocks Qiagen’s bid to invalidate diagnostics patent

20 July 2020 Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.

More on this story

MSF challenges Gilead patent in China

20 June 2018 Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.

PTAB shoots down tenth I-MAK Gilead challenge

24 July 2018 The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

Biotechnology

PTAB blocks Qiagen’s bid to invalidate diagnostics patent

20 July 2020 Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent